亚洲狠狠婷婷综合久久蜜芽,午夜在线观看成人av,欧美国产日韩a在线视频

普沙托韋

NMR下載 COA and HPLC MSDS下載
names：
Presatovir
CAS號：
1353625-73-6
MDL Number： No data available
MF(分子式)： C24H30ClN7O3S MW(分子量)： 532.06
EINECS:No data available Reaxys Number:No data available
Pubchem ID:58029842 Brand:BIOFOUNT

普沙托韋(1353625-73-6,Presatovir)是人類呼吸道合胞病毒（RSV）融合蛋白（F蛋白）抑制劑，普沙托韋具有潛在的抗病毒活性。普沙托韋與病毒表面的F蛋白特異性結合，從而抑制RSV F蛋白介導的與宿主細胞膜的融合并阻止病毒進入。

貨品編碼	規格	純度	價格 (￥)	現價(￥)	特價(￥)	庫存描述	數量	總計 (￥)
YZM000866-10mg	10mg	99.9%	￥ 6076.00	￥ 6076.00		2-3天	- +	￥ 0.00
YZM000866-5mg	5mg	99.9%	￥ 3412.00	￥ 3412.00		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯系人：

*電話：

*驗證碼：

詢價

中文別名	普沙托韋(1353625-73-6,Presatovir);GS-5806
英文別名	Presatovir(1353625-73-6,GS-5806)
CAS號	1353625-73-6
Inchi	InChI=1S/C24H30ClN7O3S/c1-15-13-32-22(27-23(15)30-10-8-17(26)14-30)12-20(28-32)21-5-3-4-9-31(21)24(33)18-11-16(25)6-7-19(18)29-36(2,34)35/h6-7,11-13,17,21,29H,3-5,8-10,14,26H2,1-2H3/t17-,21-/m0/s1
InchiKey	GOFXWTVKPWJNGD-UWJYYQICSA-N
分子式 Formula	C24H30ClN7O3S
分子量 Molecular Weight	532.06
溶解度Solubility	DMSO >15 mg/ml
性狀	灰白色至淺黃色固體粉末
儲藏條件 Storage conditions	-20°C 3 years年 4°C 2 years年 / 溶液中:-80°C 6 months月 -20°C 1 month月

普沙托韋(1353625-73-6,Presatovir)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染

Presatovir(1353625-73-6,GS-5806) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:普沙托韋(1353625-73-6,Presatovir),普沙托韋試劑,普沙托韋抑制劑,普沙托韋的純度,普沙托韋雜質,普沙托韋的含量,普沙托韋的作用,普沙托韋的使用,普沙托韋的外觀,普沙托韋的溶解度,普沙托韋的合成,普沙托韋的生產,普沙托韋的性質

產品說明	普沙托韋(1353625-73-6,Presatovir)是人類呼吸道合胞病毒（RSV）融合蛋白（F蛋白）抑制劑，普沙托韋具有潛在的抗病毒活性。
Introduction	Presatovir(1353625-73-6,普沙托韋) is an orally available inhibitor of human respiratory syncytial virus (RSV) fusion protein (F protein), with potential antiviral activity.
Application1	普沙托韋(1353625-73-6,Presatovir)可以通過阻斷病毒細胞融合過程來抑制多種呼吸道合胞病毒臨床分離株。
Application2	普沙托韋(1353625-73-6,Presatovir)也可以抑制融合前或融合后呼吸道合胞病毒的構象變化
Application3	Presatovir has been used in trials studying the treatment of RSV Infection, Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus Infections, and Respiratory Syncytial Virus (RSV) Infections.

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續沖洗+P337如果眼睛刺激持續+P2393獲得醫療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

Impact of Respiratory Virus Infections in Exacerbation of Acute and Chronic Rhinosinusitis(Current Allergy and Asthma Reports,2017)

Antiviral Consideration for Transplantation Including Drug Resistance(Principles and Practice of Transplant Infectious Diseases,2019)

Recent Developments in Infectious Disease Chemotherapy: Review for Emergency Department Practitioners 2020

The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral Session(Bone Marrow Transplantation,2018)

Respiratory Viral Infections in Transplant Recipients(Principles and Practice of Transplant Infectious Diseases,2019)

Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study
Abstract:GS-5806 is a novel, orally bioavailable RSV fusion inhibitor discovered following a lead optimization campaign on a screening hit. The oral absorption properties were optimized by converting to the pyrazolo[1,5-a]-pyrimidine heterocycle, while potency, metabolic, and physicochemical properties were optimized by introducing the para-chloro and aminopyrrolidine groups. A mean EC50 = 0.43 nM was found toward a panel of 75 RSV A and B clinical isolates and dose-dependent antiviral efficacy in the cotton rat model of RSV infection. Oral bioavailability in preclinical species ranged from 46 to 100%, with evidence of efficient penetration into lung tissue. In healthy human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a mean 4.2 log10 reduction in peak viral load and a significant reduction in disease severity compared to placebo. In conclusion, a potent, once daily, oral RSV fusion inhibitor with the potential to treat RSV infection in infants and adults is reported.

GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein
Abstract:GS-5806 is a small-molecule inhibitor of human respiratory syncytial virus fusion protein-mediated viral entry. During viral entry, the fusion protein undergoes major conformational changes, resulting in fusion of the viral envelope with the host cell membrane. This process is reproduced in vitro using a purified, truncated respiratory syncytial virus (RSV) fusion protein. GS-5806 blocked these conformational changes, suggesting a possible mechanism for antiviral activity.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開